Q3 Earnings Forecast for LMAT Issued By Barrington Research

LeMaitre Vascular, Inc. (NASDAQ:LMAT) – Research analysts at Barrington Research lifted their Q3 2025 EPS estimates for shares of LeMaitre Vascular in a report issued on Friday, February 28th. Barrington Research analyst M. Petusky now forecasts that the medical instruments supplier will earn $0.57 per share for the quarter, up from their prior estimate of $0.55. Barrington Research has a “Market Perform” rating on the stock. The consensus estimate for LeMaitre Vascular’s current full-year earnings is $1.94 per share. Barrington Research also issued estimates for LeMaitre Vascular’s Q4 2025 earnings at $0.60 EPS, FY2025 earnings at $2.30 EPS, Q1 2026 earnings at $0.60 EPS, Q2 2026 earnings at $0.69 EPS, Q3 2026 earnings at $0.65 EPS, Q4 2026 earnings at $0.68 EPS and FY2026 earnings at $2.62 EPS.

LeMaitre Vascular (NASDAQ:LMAT) last released its quarterly earnings data on Thursday, February 27th. The medical instruments supplier reported $0.49 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.49. The company had revenue of $55.81 million during the quarter, compared to analyst estimates of $55.99 million. LeMaitre Vascular had a net margin of 19.40% and a return on equity of 13.15%.

A number of other equities research analysts have also issued reports on LMAT. Wells Fargo & Company started coverage on LeMaitre Vascular in a research note on Thursday, February 13th. They issued an “equal weight” rating and a $95.00 target price for the company. StockNews.com downgraded shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a research report on Friday, December 13th. Oppenheimer lowered shares of LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a research note on Friday, February 28th. Finally, Lake Street Capital upped their target price on shares of LeMaitre Vascular from $105.00 to $110.00 and gave the company a “buy” rating in a research note on Friday, February 28th. Five research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $95.25.

LeMaitre Vascular Trading Down 1.8 %

Shares of NASDAQ LMAT opened at $90.47 on Monday. The stock has a fifty day moving average price of $96.87 and a 200 day moving average price of $95.00. The company has a market cap of $2.03 billion, a P/E ratio of 49.44, a P/E/G ratio of 2.22 and a beta of 0.96. LeMaitre Vascular has a 12-month low of $62.39 and a 12-month high of $109.58.

Institutional Trading of LeMaitre Vascular

Several institutional investors have recently added to or reduced their stakes in LMAT. New York State Teachers Retirement System increased its position in shares of LeMaitre Vascular by 1.2% in the 4th quarter. New York State Teachers Retirement System now owns 8,189 shares of the medical instruments supplier’s stock worth $755,000 after purchasing an additional 100 shares during the last quarter. Flputnam Investment Management Co. increased its holdings in LeMaitre Vascular by 3.6% in the fourth quarter. Flputnam Investment Management Co. now owns 2,923 shares of the medical instruments supplier’s stock valued at $269,000 after buying an additional 102 shares during the last quarter. Norden Group LLC raised its stake in LeMaitre Vascular by 4.5% during the fourth quarter. Norden Group LLC now owns 2,371 shares of the medical instruments supplier’s stock valued at $218,000 after buying an additional 103 shares in the last quarter. Blue Barn Wealth LLC raised its stake in LeMaitre Vascular by 4.4% during the fourth quarter. Blue Barn Wealth LLC now owns 2,485 shares of the medical instruments supplier’s stock valued at $229,000 after buying an additional 104 shares in the last quarter. Finally, Shaker Investments LLC OH lifted its holdings in LeMaitre Vascular by 0.8% during the 4th quarter. Shaker Investments LLC OH now owns 13,948 shares of the medical instruments supplier’s stock worth $1,285,000 after buying an additional 112 shares during the last quarter. 84.64% of the stock is owned by institutional investors and hedge funds.

LeMaitre Vascular Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, March 27th. Stockholders of record on Thursday, March 13th will be given a dividend of $0.20 per share. The ex-dividend date is Thursday, March 13th. This represents a $0.80 dividend on an annualized basis and a dividend yield of 0.88%. This is an increase from LeMaitre Vascular’s previous quarterly dividend of $0.16. LeMaitre Vascular’s dividend payout ratio (DPR) is presently 41.24%.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.